Anneli Elme
About
Anneli Elme is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Anneli Elme has authored 23 papers receiving a total of 524 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Anneli Elme's work include Gastric Cancer Management and Outcomes (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Gastrointestinal Tumor Research and Treatment (4 papers). Anneli Elme is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Gastrointestinal Tumor Research and Treatment (4 papers). Anneli Elme collaborates with scholars based in Estonia, United States and South Korea. Anneli Elme's co-authors include Tiina Saarto, Hannu Kautiainen, Carl Blomqvist, Salme Järvenpää, Heidi Penttinen, Riku Nikander, Riikka Huovinen, Meri Utriainen, Leena Vehmanen and Johanna Ruohola and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.
In The Last Decade
Anneli Elme
22 papers receiving 511 citations
Peers
Anneli Elme
Felicitas Lenz Germany
Clara Castro Portugal
Willemieke P.M. Dijksterhuis Netherlands
Seung Soo Lee South Korea
David Cade United Kingdom
Margreet van Putten Netherlands
Stefano Lamon Italy
Margaret M. Byrne United States
Rasmus Dahlin Bojesen Denmark
Les Bokey Australia
Citations per year, relative to Anneli Elme Anneli Elme (= 1×)
peers
Felicitas Lenz
Countries citing papers authored by Anneli Elme
Since
Specialization
Citations
This map shows the geographic impact of Anneli Elme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anneli Elme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anneli Elme more than expected).
Fields of papers citing papers by Anneli Elme
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anneli Elme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anneli Elme. The network helps show where Anneli Elme may publish in the future.
Co-authorship network of co-authors of Anneli Elme
This figure shows the co-authorship network connecting the top 25 collaborators of Anneli Elme. A scholar is included among the top collaborators of Anneli Elme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anneli Elme. Anneli Elme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rha, Sun Young, Ana Fernández Montés, Shu Qin, et al.. (2025). LBA10 Bemarituzumab (BEMA) plus chemotherapy for advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC): FORTITUDE-101 phase III study results. Annals of Oncology. 36. S1620–S1620.
2.
Rha, Sun Young, Yanqiao Zhang, Anneli Elme, et al.. (2025). Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial. JCO Precision Oncology. 9(9). e2400710–e2400710.
3.
Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2025). EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: Overall survival results.. Journal of Clinical Oncology. 43(4_suppl).
4.
Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2023). O-5 Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG. Annals of Oncology. 34. S182–S182.
5.
Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2023). Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group.. Journal of Clinical Oncology. 41(16_suppl). 4057–4057.
6.
Fuchs, Charles S., Mustafa Özgüroğlu, Yung‐Jue Bang, et al.. (2021). Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 25(1). 197–206.
7.
Derksen, Jeroen W. G., Graham Warren, Karin Jordan, et al.. (2020). European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment. European Journal of Cancer. 138. 99–108.
8.
Elme, Anneli, et al.. (2020). Changes in the quality of care of colorectal cancer in Estonia: a population-based high-resolution study. BMJ Open. 10(10). e035556–e035556.
9.
Tasmuth, Tiina, Juho T. Lehto, Hannu Kautiainen, et al.. (2018). Cancer Patients' Symptom Burden and Health-related Quality of Life (HRQoL) at Tertiary Cancer Center from 2006 to 2013: A Cross-sectional Study. Anticancer Research. 39(1). 271–277.
10.
Kim, Tae Won, Anneli Elme, Joon Oh Park, et al.. (2018). Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 17(3). 206–214.
11.
Ajani, Jaffer A., Mikhail Abramov, Igor Bondarenko, et al.. (2017). A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Annals of Oncology. 28(9). 2142–2148.
12.
Kim, Tae Won, Anneli Elme, Joon Ho Park, et al.. (2017). Early tumor shrinkage (ETS) and depth of response (DpR) in wild-type (WT) RAS tumors from the phase III trial of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(15_suppl). 3561–3561.
13.
Kim, Tae Won, Anneli Elme, Zvonko Kusić, et al.. (2016). A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. British Journal of Cancer. 115(10). 1206–1214.
14.
Kim, Tae Won, Anneli Elme, Zvonko Kusić, et al.. (2016). Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 34(15_suppl). 3536–3536.
15.
Kim, Tae Won, Anneli Elme, Zvonko Kusić, et al.. (2016). An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.. Journal of Clinical Oncology. 34(4_suppl). 642–642.
16.
Elme, Anneli, Tiina Saarto, K. J. Tötterman, et al.. (2013). Electrocardiography changes during adjuvant breast cancer therapy: incidence and risk factors.. PubMed. 33(11). 4933–9.
17.
Elme, Anneli, Meri Utriainen, T Palva, et al.. (2013). Obesity and physical inactivity are related to impaired physical health of breast cancer survivors.. PubMed. 33(4). 1595–602.
18.
Saarto, Tiina, Harri Sievänen, Pirkko Kellokumpu‐Lehtinen, et al.. (2011). Effect of supervised and home exercise training on bone mineral density among breast cancer patients. A 12-month randomised controlled trial. Osteoporosis International. 23(5). 1601–1612.
19.
Penttinen, Heidi, Tiina Saarto, Pirkko Kellokumpu‐Lehtinen, et al.. (2010). Quality of life and physical performance and activity of breast cancer patients after adjuvant treatments. Psycho-Oncology. 20(11). 1211–1220.
20.
Hecht, J. Randolph, et al.. (2009). 6584 A phase III study of CapeOx +/− lapatinib in HER2 positive locally-advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results. European Journal of Cancer Supplements. 7(2). 385–385.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Felicitas Lenz Breakdown of academic impact, for papers by Clara Castro Breakdown of academic impact, for papers by Willemieke P.M. Dijksterhuis Breakdown of academic impact, for papers by Seung Soo Lee Breakdown of academic impact, for papers by David Cade Breakdown of academic impact, for papers by Margreet van Putten Breakdown of academic impact, for papers by Stefano Lamon Breakdown of academic impact, for papers by Margaret M. Byrne Breakdown of academic impact, for papers by Rasmus Dahlin Bojesen Breakdown of academic impact, for papers by Les Bokey